Risk factors for potential drug-drug interactions in patients with myasthenia gravis.

Dejan Z AleksićAleksandra DimitrijevićSrđan M StefanovićAndriana BukonjićJovana Z Milosavljević Slobodan M JankovicIvo BožovićStojan PerićDragana Lavrnić

Published in: Neurological research (2021)

The frequency of the pDDIs in hospitalized MG patients is high, and adversely influenced by dyspnea, generalized MG, diabetes mellitus, hypertension, total number of drugs-used and use of antiplatelets.

Keyphrases

myasthenia gravis
end stage renal disease
newly diagnosed
blood pressure
chronic kidney disease
adipose tissue
patient reported outcomes
skeletal muscle
palliative care
insulin resistance
adverse drug